US tariff threat on Indian generics: What it means for pharma

Tariffs on Indian generics could raise US drug prices, disrupt supply chains, and strain insurance systems. Indian firms, reliant on US revenue, may adapt by focusing on APIs and high-margin segments. Strategic partnerships could mitigate impacts, positioning them competitively in the global market.